{"entity":{"id":"nct07796763","kind":"trial","name":"A Global Trial of Trastuzumab Rezetecan (SHR-A1811) in Combination With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Colorecta","aka":["HORIZON-CRC221"],"tldr":"A phase 2 trial in colorectal cancer, run by Jiangsu HengRui Medicine Co., Ltd., not yet recruiting.","summary":"A Global Trial of Trastuzumab Rezetecan (SHR-A1811) in Combination With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Colorectal Cancer Expressing HER2 is a phase 2, randomised interventional study registered as NCT07796763 by Jiangsu HengRui Medicine Co., Ltd., with a registry enrolment figure of 48 participants, started 2026-11-01 and due to reach its primary completion in 2028-05-01. Interventions recorded: Trastuzumab Rezetecan (SHR-A1811) injection; high dose; Trastuzumab Rezetecan (SHR-A1811) injection; low dose. Conditions listed: Advanced Colorectal Cancer Expressing HER2. Primary outcome: Incidence of treatment-emergent adverse events; Determination of the recommended phase 3 dose. Colorectal eligibility wording from the registry: \"Histologically or cytologically confirmed unresectable, recurrent, or metastatic colorectal adenocarcinoma that is HER2-positive\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07796763","url":"https://clinicaltrials.gov/study/NCT07796763"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer","her2-amplified-colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07796763","phase":"2","setting":"A Global, Multicenter, Randomized, Dose-Optimization Phase II Study of Trastuzumab Rezetecan (SHR-A1811) in Combination With mFOLFOX6 (-1) and Bevacizumab as First-Line Treatment in Patients With HER2-Positive Advanced Colorectal Cancer (HORIZON-CRC221)","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","enrolled":48,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07796763/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"her2-amplified-colorectal","kind":"cancer","name":"HER2-amplified colorectal cancer","route":"/cancers/her2-amplified-colorectal/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}